This Health Advisory discusses an early increase in respiratory syncytial virus (RSV) activity in California.

Providers are advised to consider testing for additional respiratory pathogens besides SARS-CoV-2, including RSV, and to administer prophylactic palivizumab to high-risk infants and young children per American Academy of Pediatrics guidance (https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/).

Please see the full CDPH Health Advisory,

Free viewers are required for some of the attached documents.
They can be downloaded by clicking on the icons below.

Acrobat Reader Windows Media Player Word Viewer Excel Viewer PowerPoint Viewer